167 related articles for article (PubMed ID: 15001966)
1. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects.
Park JY; Kim KA; Kang MH; Kim SL; Shin JG
Clin Pharmacol Ther; 2004 Mar; 75(3):157-62. PubMed ID: 15001966
[TBL] [Abstract][Full Text] [Related]
2. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.
Niemi M; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2004 Sep; 76(3):239-49. PubMed ID: 15371985
[TBL] [Abstract][Full Text] [Related]
3. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects.
Park JY; Kim KA; Shin JG; Lee KY
Br J Clin Pharmacol; 2004 Oct; 58(4):397-402. PubMed ID: 15373932
[TBL] [Abstract][Full Text] [Related]
4. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.
Park JY; Kim KA; Park PW; Park CW; Shin JG
Clin Pharmacol Ther; 2003 Oct; 74(4):334-40. PubMed ID: 14534520
[TBL] [Abstract][Full Text] [Related]
5. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
6. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects.
Kim KA; Park PW; Kim HK; Ha JM; Park JY
J Clin Pharmacol; 2005 Aug; 45(8):941-6. PubMed ID: 16027405
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Kirchheiner J; Thomas S; Bauer S; Tomalik-Scharte D; Hering U; Doroshyenko O; Jetter A; Stehle S; Tsahuridu M; Meineke I; Brockmöller J; Fuhr U
Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers.
Fischer TL; Pieper JA; Graff DW; Rodgers JE; Fischer JD; Parnell KJ; Goldstein JA; Greenwood R; Patterson JH
Clin Pharmacol Ther; 2002 Sep; 72(3):238-46. PubMed ID: 12235444
[TBL] [Abstract][Full Text] [Related]
9. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron.
Villikka K; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Apr; 65(4):377-81. PubMed ID: 10223773
[TBL] [Abstract][Full Text] [Related]
10. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
11. Effect of rifampicin on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ
Br J Clin Pharmacol; 2006 Jan; 61(1):70-8. PubMed ID: 16390353
[TBL] [Abstract][Full Text] [Related]
12. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Niemi M; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Apr; 69(4):194-200. PubMed ID: 11309547
[TBL] [Abstract][Full Text] [Related]
13. Rifampin reduces plasma concentrations and effects of zolpidem.
Villikka K; Kivistö KT; Luurila H; Neuvonen PJ
Clin Pharmacol Ther; 1997 Dec; 62(6):629-34. PubMed ID: 9433391
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate.
Borin MT; Chambers JH; Carel BJ; Gagnon S; Freimuth WW
Clin Pharmacol Ther; 1997 May; 61(5):544-53. PubMed ID: 9164416
[TBL] [Abstract][Full Text] [Related]
15. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.
Kyrklund C; Backman JT; Kivistö KT; Neuvonen M; Laitila J; Neuvonen PJ
Clin Pharmacol Ther; 2000 Dec; 68(6):592-7. PubMed ID: 11180018
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics.
Harris RZ; Inglis AM; Miller AK; Thompson KA; Finnerty D; Patterson S; Jorkasky DK; Freed MI
J Clin Pharmacol; 1999 Nov; 39(11):1189-94. PubMed ID: 10579151
[TBL] [Abstract][Full Text] [Related]
17. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
[TBL] [Abstract][Full Text] [Related]
18. Effect of voriconazole on the pharmacokinetics of diclofenac.
Hynninen VV; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Laine K
Fundam Clin Pharmacol; 2007 Dec; 21(6):651-6. PubMed ID: 18034666
[TBL] [Abstract][Full Text] [Related]
19. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
[TBL] [Abstract][Full Text] [Related]
20. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.
Kim KA; Park PW; Liu KH; Kim KB; Lee HJ; Shin JG; Park JY
J Clin Pharmacol; 2008 Jan; 48(1):66-72. PubMed ID: 18094221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
